eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
1-2/2006
vol. 31
 
Share:
Send email
Share:
abstract:

Clinical immunology
Enoxaparine treatment enhanced angiogenic activity of mouse and human serum

Leszek Jung
,
Ewa Skopińska-Różewska
,
Paweł Małdyk
,
Ewa Sommer
,
Bożena Wojciechowska
,
Joanna Chorostowska-Wynimko
,
Janusz Bany
,
Andrzej K. Siwicki
,
Barbara Lisowska

(Centr Eur J Immunol 2006; 31 (1-2): 6-10)
Online publish date: 2006/10/12
View full text Get citation
 
Regenerative processes play essential role in hard and soft tissues repair and are tightly connected with angiogenesis. During the wound healing angiogenic factors are released and found in the circulating blood. Enoxaparine (En) and nadroparine (Nad), low-molecular weight heparins (LMW) are routinely used as anti-coagulants for prophylaxis after bone surgery. The aim of this study was to evaluate the in vivo angiogenic potency and VEGF and bFGF content of sera collected from seven patients after hip surgery, treated for 14 days with 40 mg of En daily. We also performed experiments with mice treated with En (80 µg) or Nad (8 IU) for 14 days. Treatment of the mice with En increased angiogenic activity and VEGF content of their sera, sera obtained from Nad mice did not differ from the controls. Sera of patients treated with En presented higher angiogenic activity as well as higher bFGF and VEGF content after 14 injections than the values observed before the beginning of the treatment. Conclusion: beneficial effect of 14-days prophylaxis with enoxaparine on healing process might be expected in patients after hip surgery.
keywords:

enoxaparine, patients, hip surgery, angiogenesis, mice
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.